Axa S.A. Has $6.43 Million Position in Organon & Co. (NYSE:OGN)

Axa S.A. cut its holdings in Organon & Co. (NYSE:OGN) by 13.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 310,500 shares of the company’s stock after selling 49,366 shares during the period. Axa S.A. owned 0.12% of Organon & Co. worth $6,427,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. Vanguard Group Inc. increased its position in Organon & Co. by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 30,789,850 shares of the company’s stock worth $578,849,000 after buying an additional 192,613 shares during the period. LSV Asset Management increased its position in Organon & Co. by 47.3% during the second quarter. LSV Asset Management now owns 6,610,768 shares of the company’s stock worth $136,843,000 after acquiring an additional 2,121,940 shares during the period. Nordea Investment Management AB raised its stake in Organon & Co. by 26.9% during the 1st quarter. Nordea Investment Management AB now owns 3,970,328 shares of the company’s stock valued at $74,563,000 after purchasing an additional 841,518 shares during the last quarter. Principal Financial Group Inc. raised its stake in Organon & Co. by 1.2% during the 1st quarter. Principal Financial Group Inc. now owns 2,853,331 shares of the company’s stock valued at $53,643,000 after purchasing an additional 35,183 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in Organon & Co. by 23.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,407,915 shares of the company’s stock valued at $49,843,000 after purchasing an additional 463,216 shares during the period. Institutional investors and hedge funds own 77.43% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on OGN shares. Evercore ISI upgraded shares of Organon & Co. to a “strong-buy” rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. downgraded Organon & Co. from a “neutral” rating to an “underweight” rating and lifted their target price for the stock from $18.00 to $20.00 in a research report on Friday, September 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $21.00.

Organon & Co. Stock Up 0.1 %

OGN opened at $19.18 on Friday. The company has a market capitalization of $4.94 billion, a P/E ratio of 4.69, a P/E/G ratio of 0.87 and a beta of 0.85. The company has a debt-to-equity ratio of 60.05, a current ratio of 1.64 and a quick ratio of 1.17. The firm’s fifty day moving average price is $20.84 and its two-hundred day moving average price is $20.14. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $23.10.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.04. Organon & Co. had a negative return on equity of 840.29% and a net margin of 15.76%. The company had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.61 billion. During the same period in the prior year, the company posted $1.31 EPS. The company’s revenue was down .1% compared to the same quarter last year. On average, analysts anticipate that Organon & Co. will post 4.14 EPS for the current year.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 12th. Shareholders of record on Friday, August 16th were paid a dividend of $0.28 per share. The ex-dividend date was Friday, August 16th. This represents a $1.12 annualized dividend and a yield of 5.84%. Organon & Co.’s dividend payout ratio is currently 27.38%.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.